Shots:

• Macrogenic plans for the onset of a trial evaluating flotetuzumab + MGA012 to broaden the DOR of flotetuzumab in AML patients. Macrogenic will regain WW rights to develop and commercialize flotetuzumab with the termination of the license agreement with Laboratoires Servier signed on Sept’2012- which will be effective on Jan 15- 2020
• MacroGenics has completed the enrollment of P-I study and will assess Flotetuzumab as monothx. in patients with primary refractory AML with its expected clinical data in H2’19
• Flotetuzumab is a bispecific DART molecule recognizing CD123 and CD3- capable of redirecting the T lymphocytes to kill CD123-expressing cells and has received FDA’s orphan drug designation for AML

Click here to read full press release/ article | Ref: MacroGenics | Image: Sign shop